PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Cancer Res. Author manuscript; available in PMC 2011 February 15.
Published in final edited form as:
PMCID: PMC2822895
NIHMSID: NIHMS166299

Noninvasive detection of target modulation following phosphatidylinositol-3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy

Abstract

Numerous mechanism-based anticancer drugs that target the phosphatidylinositol-3-kinase (PI3K) signaling pathway are in clinical trials. However, assessment of response using traditional imaging methods remains a challenge, as it is often associated with tumor stasis. Here we show for the first time the efficacy of hyperpolarized 13C magnetic resonance spectroscopy (MRS) in detecting the effect of PI3K signaling inhibition by monitoring hyperpolarized [1-13C]-lactate levels produced from hyperpolarized [1-13C]-pyruvate through lactate dehydrogenase (LDH) activity. Studies were performed on GS-2 glioblastoma and MDA-MB-231 breast adenocarcinoma cells. Following inhibition of signaling, hyperpolarized lactate dropped significantly to 42±12% and 76±5% in GS-2 cells treated with LY294002 and everolimus respectively and to 71±15% in MDA-MB-231 cells treated with LY294002. This correlated with a drop in LDH activity to 48±4%, 63±4% and 69±12%, and was associated with a drop in LDHA mRNA levels and LDHA and HIF-1α protein levels. Taken together the data demonstrate that hyperpolarized 13C MRS of pyruvate can be used to monitor the drop in LDHA activity and expression following reduced HIF-1α levels resulting from PI3K signal inhibition. In line with these findings, in vivo studies of GS-2 subcutaneous xenografts treated with everolimus resulted in inhibition in tumor growth, which was associated with a drop in the hyperpolarized lactate-to-pyruvate ratio. In contrast an increase in the ratio was detected in controls. This works demonstrates the potential of hyperpolarized 13C MRS for noninvasive imaging of drug target modulation by treatments that modulate PI3K signaling and HIF-1α levels.

Keywords: MRS, PI3K inhibition, hyperpolarized 13C, DNP

INTRODUCTION

The phosphatidylinositol-3-kinase (PI3K) pathway plays an integral role in the regulation of many key cellular processes, mediating proliferation, differentiation, intracellular signaling, and glucose metabolism (1). Constitutive signaling through deregulation of the pathway is common in human cancers, and drives tumor development by inducing angiogenesis, motility, invasion, progression, and survival (2). The PI3K pathway is one of the most frequently activated, with current estimates indicating that mutations in at least one of the pathway components account for up to 30% of all sporadic human cancers (3, 4). Given the importance of this signaling pathway in oncogenesis, it provides an attractive target for mechanism-based anticancer treatments (5, 6). Accordingly, several PI3K inhibitors are currently in clinical trials with promising results in glioblastoma, breast, hematological and non-small cell lung cancer studies (7).

Response to PI3K inhibition is often associated with tumor stasis rather than shrinkage (8, 9). Consequently, the utility of such traditional imaging methods as computed tomography and magnetic resonance imaging (MRI) in monitoring early response is limited. Current clinical trials resort to either indirect methods, such as inspection of peripheral blood mononuclear cells for drug-induced molecular effects, or highly invasive methods, such as monitoring of sequential tumor biopsies (10, 11). For this reason, identifying novel biomarkers of target inhibition that are detectable by noninvasive methods is essential for determining the efficacy of treatment and correlation with antitumor effects (7, 12).

Magnetic resonance spectroscopy (MRS) is a noninvasive, radiation-free method that has been valuable for informing on biochemical composition of cancer cells and providing metabolic imaging biomarkers of cell transformation and response to treatment (1318). We have used MRS to identify biomarkers of response to emerging targeted therapies (1923). In particular, we have shown that inhibition of the PI3K pathway by LY294002 or wortmannin is associated in cells with a drop in phosphocholine (PC) (22). Consistent with this finding, in vivo treatment with the bioavailable wortmannin analogue PX-866 resulted in a drop in choline-containing metabolites in an orthotopic brain tumor model (23).

13C MRS methods can also be used to inform on cellular metabolism, but application has been limited due to low sensitivity. However, recent advances in dynamic nuclear polarization (DNP) and its application to solution-state magnetic resonance provide a signal enhancement of over 10,000-fold compared to conventional 13C MRS (24). The dramatically improved signal-to-noise ratio (SNR) has enabled the real-time investigation of previously unexplored metabolic reactions (2529). In particular, this method has been used to monitor pyruvate metabolism in vivo and in cells to demonstrate an increase in pyruvate-to-lactate conversion in cancer, consistent with the increase in lactate dehydrogenase (LDH) activity (25, 29). In a prostate cancer model, elevated hyperpolarized lactate and an increase in the ratio of hyperpolarized lactate to total hyperpolarized carbon species was associated with histological grade (29). In other studies, a drop in hyperpolarized lactate formation was observed following chemotherapeutic treatment, a result of the apoptotically induced depletion of NADH, the cofactor of LDH (27).

Hyperpolarized 13C MRS of pyruvate has unrealized potential for monitoring therapies specifically targeted at key carcinogenic pathways. The modulation of energy production and its interplay with altered cell signaling has received substantial attention in recent years (30, 31) and it is clear that PI3K signaling has direct effects on glucose metabolism (32). Several putative interactions exist but it is likely that the predominant link is through mTOR-activated post-transcriptional control of hypoxia-inducible factor 1 (HIF-1) (3335), which controls the expression of several glycolytic enzymes, including the LDH subunit LDHA (32, 36, 37). Based on this knowledge, we hypothesized that PI3K signaling would directly affect cellular LDH activity and that this could be monitored using hyperpolarized 13C MRS by observing the formation of hyperpolarized lactate from introduced hyperpolarized pyruvate. Treatment with a PI3K inhibitor would negatively modulate hyperpolarized lactate formation. Hyperpolarized lactate would thus provide a biomarker of PI3K signaling inhibition.

To test this hypothesis, we investigated two cancer cell lines treated with inhibitors of PI3K signaling. We observed that signal inhibition resulted in a significant reduction in hyperpolarized lactate and show that this reduction is due to partial silencing of HIF-1-regulated expression of LDHA and a resulting drop in LDH activity. Our results indicate, to our knowledge for the first time, that hyperpolarized 13C MRS could be used to monitor PI3K signal inhibition, and thus can address the need for a noninvasive approach to monitor the efficacy of PI3K-targeted drug treatments.

MATERIALS AND METHODS

Cell culture

GS-2 cells were supplied by Dr. Haas-Kogan and Dr. James (University of California, San Francisco) and MDA-MB-231 cells by Dr. Lotan (University of Texas M. D. Anderson Cancer Center). Unique DNA “fingerprint” identities (i.e., variable number tandem repeat polymerase chain reaction products) have been established for the cell lines used in this study, and the identities of these cell lines were confirmed in association with their use in the experiments described here.

Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 100 units/mL penicillin and 100 μg/mL streptomycin. DMEM used for culturing of GS-2 was supplemented with an additional 1 mM of Na-pyruvate and 28 mM glucose. Custom-made DMEM with 0.22 g/L inorganic phosphate (Pi; UCSF Cell Culture Facility) was used in MRS studies. For all experiments, cells were harvested in their logarithmic phase of proliferation.

For PI3K inhibition, cells were incubated with 50 μM LY294002. GS-2 cells were treated for 48 hrs and MDA-MB-231 cells were treated for 40 hrs, based on previous work (22). For mTOR inhibition cells were treated for 48 hrs with 100 μm everolimus (Molcan Corporation Toronto Canada). To monitor the effect of a DNA damaging agent cells were treated for 48 hrs with 100 nM temozolomide (Tecoland Corp; Edison, NJ). The final concentration of DMSO used to dissolve all inhibitors was 1:1000 in culture medium.

Cell proliferation assay

The effect of drug treatment on cell proliferation was determined using the WST-1 reagent assay (Roche; Indianapolis, IN). Cells were seeded in 96-well plates and treated for 4 to 48 hr. After treatment, WST-1 reagent was incubated in wells for 2 hr and cell viability determined by quantification of absorbance at 440 nm using a spectrophotometer (Tecan; Mannedorf, SUI).

Perfused cell system setup

For MRS studies, cells were encapsulated in agarose beads, essentially as described (38). Independent of whether cells were treated with drug or not, the same number of cells (1.5–2×108 for GS-2 and 7–8×107 for MDA-MB-231) was investigated. After encapsulation, beads were incubated overnight in growth medium prior to MRS experiments.

The beads were loaded into an NMR-compatible perfusion system, modified from previously described (38). Briefly, the perfusion system consisted of three tubing lines to circulate medium to a 10-mm NMR tube and one tubing line to deliver 5% CO2. A three-way valve allowed for introduction of hyperpolarized material to the inflow line. 100 mL of perfusion medium was circulated at 1.5 mL/min throughout the MRS studies. Medium circulation was stopped briefly during injection of hyperpolarized pyruvate and acquisition of 13C spectra. The NMR probe was maintained at 35°C.

31P MRS acquisition and analysis

31P MRS spectra were acquired on a 500-MHz INOVA spectrometer (Varian; Palo Alto, CA) using a pulse-acquire scheme (30° pulse, 3 sec repetition time) and composite pulse 1H decoupling during acquisition. The resulting spectra were analyzed using ACD/Spec Manager version 9.15 (Advanced Chemistry Development; Toronto, Canada). Metabolite concentrations were calculated from peak areas determined by deconvolution, with correction for saturation and normalization to both internal reference (Pi, 1.87 μM) and cell number.

Hyperpolarization

Samples of [1-13C]-pyruvic acid (Isotech; Champaign, IL) containing 15 mM of the trityl radical OX063 (Oxford Instruments; Abingdon, UK) were hyperpolarized using the Hypersense DNP (Oxford Instruments) polarizer as described (26, 29). After 1.5 hr, polarized pyruvic acid was rapidly dissolved in 6.0 mL of isotonic 40 mM Tris-based buffer containing 3.0 μM EDTA (pH 7.8) and injected into the perfusion system within 15 sec.

13C MRS acquisition and analysis

Single transient 13C spectra were acquired every 3 sec for 300 sec. In experiments with GS-2 cells, 13° excitation pulses were used. Experiments with MDA-MB-231 used 5° pulses. The intensities of lactate peaks were quantified by integration using ACD/Spec Manager. To correct for small variations in the degree of polarization, peak area values of individual hyperpolarized species were normalized to the peak area of all hyperpolarized species at maximum value (predominantly pyruvate, occurring immediately after injection). In addition, values were normalized to cell number.

Two approaches were used to determine the effect of PI3K inhibition on hyperpolarized lactate formation. First, maximum lactate levels per cell (Lacmax) were determined and compared in control and treated cells exposed to the same pyruvate concentrations. Second, the apparent pseudo-rate of lactate production was determined and compared. For this, we used Bloch equations modified for two-site chemical exchange similarly to previously described (39). Briefly, we considered the chemical equilibrium between pyruvate (Pyr) and lactate (Lac) catalyzed by LDH (Eq. 1):

equation M1
(1)

where kPyr and kLac are the unidirectional rate constants of pyruvate-to-lactate conversion and lactate-to-pyruvate conversion, respectively. After injection of hyperpolarized [1-13C] pyruvate, the time courses of pyruvate and lactate longitudinal magnetizations, Pyrz(t) and Lacz(t), were modeled (Eq. 23):

equation M2
(2)

equation M3
(3)

where ρPyr and ρLac are the spin lattice relaxation rates (1/T1(Pyr, Lac)), t is time, Pyrz∞ and Lacz∞ are the equilibrium magnetizations of Pyr and Lac, respectively. Using these equations, the peak integrals of pyruvate and lactate versus time were fit using a non-linear least squares algorithm implemented in Matlab® (The MathWorks Inc.; Natick, MA), leading to the estimation of kPyr, kLac and ρPyr=ρLac. Monte Carlo simulation was also performed in order to assess the accuracy on the three fitted parameters.

Lactate dehydrogenase activity

The activity of LDH was measured in cell lysates by monitoring NADH consumption after addition of varying concentrations of pyruvate as described (40) by monitoring absorbance at 340 nm for 10 min using an Infinite M200 spectrophotometer (Tecan). KM and Vmax values were then determined by fitting the initial velocity plots using a Lineweaver-Burke plot.

Gene expression of lactate dehydrogenase A

Total cellular RNA was extracted by RNeasy Mini kit (Qiagen; Valencia, CA). The quantity of total RNA was determined using a Nano-Drop ND1000 Fluorospectrometer (NanoDrop Technologies; Wilmington, DE). Reverse transcription was performed using the QuantiTect Reverse Transcription kit (Qiagen). Real-time PCR of resulting cDNA was performed on a Taqman 7900 (Applied Biosystems; Foster City, CA). Expression of LDHA was examined using Assays-on-Demand (Applied Biosystems), and compared to the housekeeping gene β-actin (Integrated DNA Technologies; Coralville, IA). All procedures were performed according to manufacturers’ instructions.

PI3K pathway protein levels

The effect of PI3K signaling inhibition on PI3K pathway protein levels was analyzed by Western blotting. Cytoplasmic and nuclear proteins were run on 4–20% gels (Bio-Rad; Hercules, CA) by SDS-PAGE method, electrotransferred onto nitrocellulose membranes, blocked and incubated with primary antibodies anti-4E-BP1, anti-phospho-4E-BP1 (Ser 65), anti-GAPDH, anti-HIF-1α, anti-LDHA (Cell Signaling) anti-LDHB (Epitomics; Burlingame, CA) and GAPDH as a loading control, then incubated with secondary antibody anti-IgG HRP-linked antibody (Cell Signaling). Immunocomplexes were visualized using ECL Western Blotting Substrate (Pierce; Rockford, IL).

NAD+/NADH assay

Concentrations of NAD+ and NADH were measured in cell extracts using an enzyme cycling method and monitoring absorbance at 570 nm as described (41).

Animals Studies

All experimental procedures were approved by the UCSF Institutional Animal Care and Use Committee. For tumor implantation, four-week-old athymic mice (Nu/Nu homozygous) were anesthetized using a mixture of ketamine/xylazine (100/20 mg.kg−1), and GS-2 cells (~1×107) were injected subcutaneously in the flank. Tumor growth was monitored weekly by caliper measurement until tumors reached ca. 6 mm in diameter. From that point, treated animals received a daily injection of everolimus (10mg.kg−1.day−1 i.p. in 20μlt) while control animals were injected daily with carrier (DMSO).

In vivo MR studies were performed on a 600 MHz wide bore vertical system (Varian Inc, Palo Alto, CA). MR imaging was performed using a Varian millipede 1H coil. A 20 mm home-built 13C surface coil, positioned at the center of the magnet and of the imaging coil, was used for hyperpolarized MRS studies. Mice were anesthetized using isoflurane (3% in O2, 1.5 L.min−1) and a catheter was secured in the tail vein. The tumor region was placed in the center of the 13C coil, and the animal was positioned in the center of the magnet using a custom built cradle. A glass tube containing 13C-enriched urea placed at the center of the surface coil was used for position and chemical shift reference.

Anatomical imaging was performed first to assess the positioning and size of the tumor (2D Spin Echo (SE), TE/TR=20/2000ms, FOV=32×32mm, matrix 256×256, slice thickness=0.5mm, gap=0.5mm, Tacq=8min32s, NT=2). [1-13C]-pyruvic acid was hyperpolarized as above. 300μl of 100 mM hyperpolarized pyruvic acid in 40 mM Tris, 100mM NaOH and 0.1 mg/L Na2EDTA was then injected via the catheter over 12s and 13C 2D-MRSI was acquired 37s after injection, the time point when, based on non-localized 13C dynamic data, the hyperpolarized 13C lactate reached a maximum as previously described (42). The 13C 2D-CSI parameters were: TE/TR=0.195/125ms, frequency dimension=512; phase dimension=8×8, SW 5000Hz, FOV= 32×32mm, Tacq=8s. A rectangular pulse, equivalent to a 20-degree flip angle at 5mm from the coil, was used for excitation.

Tumor volume was calculated from caliper measurements and confirmed from SE images assuming an ellipsoid shape (volume=4/3.π.a.b.c). 13C 2D-MRSI data were processed using jMRUI software (43). For each voxel, the amplitudes of lactate and pyruvate were quantified using the AMARES package for MRSI and the lactate-to-pyruvate ratio was calculated as the ratio of the amplitudes (42). From the overlap between anatomical images and MRSI data, the voxels representing more than 75% tumor were considered as tumor voxels and the lactate-to-pyruvate ratios from these voxels were averaged.

Statistical analysis

Two-tailed unpaired Student’s t test was used to verify the statistical significance of the results, with a P ≤ 0.05 considered to be significant. All results are expressed as mean±SD and represent an average of 3 repeats unless otherwise stated.

RESULTS

In this study we monitored the effect of PI3K inhibition on cellular metabolism. We first investigated the GS-2 glioblastoma cell line and then assessed the generality of our findings by investigating the MDA-MB-231 breast cancer cell line and by probing GS-2 xenografts.

LY294002 leads to inhibition of signaling and cell proliferation in GS-2 cells

The effectiveness of LY294002 in achieving suppression of signal propagation through the PI3K pathway in treated GS-2 cells was first assessed by probing phosphorylated 4E-BP1, downstream of mTOR. Western blotting revealed that phospho-4E-BP1 was substantially lower following LY294002 treatment, confirming signaling blockage (Fig. 1A).

Figure 1
Effect of LY294002 on PI3K signaling in GS-2 cells. A, Western blots showing depletion of phospho-4E-BP1 levels in GS-2 following a 48-hr exposure to 50 μM LY294002. Total 4E-BP1 is shown as a loading control. B, WST-1 cell proliferation assay ...

Consistent with inhibition of PI3K signaling, cessation of proliferation was seen after treatment (Fig. 1B). The WST-1 cell proliferation assay showed that after 48 hr the number of treated cells had increased only 49±10% (P=0.01) whereas the number of control cells increased 385±84% (P=0.03), resulting in a significant difference between control and LY294002-treated samples (P=0.02).

Hyperpolarized 13C MRS detects a drop in hyperpolarized lactate following PI3K inhibition in GS-2 cells

Hyperpolarized 13C MRS dynamic studies were performed using hyperpolarized [1-13C]-pyruvate to visualize the LDH-catalyzed conversion of pyruvate to lactate. Figure 2A is a representative 13C spectrum recorded following injection of hyperpolarized pyruvate. Resonances from pyruvate (171 ppm), pyruvate hydrate (179 ppm) and lactate (183 ppm) were identified. Buildup of pyruvate occurs immediately after its injection (Fig. 2B). Shortly after hyperpolarized pyruvate reaches the cells, lactate appears as pyruvate undergoes reduction, retaining the polarized label. This results in an initial increase in lactate, after which decay of polarization is evident for both pyruvate and lactate.

Figure 2
Conversion of hyperpolarized [1-13C]-pyruvate to [1-13C]-lactate in a GS-2 perfused cell experiment. A, Representative 13C spectrum 45 sec after the addition of hyperpolarized [1-13C]-pyruvate (final concentration of 1 mM). Resonances for pyruvate, pyruvate ...

Injections resulting in a final concentration of 1.0 mM pyruvate were administered to control and LY294002-treated cells. Conversion of hyperpolarized pyruvate to lactate was observed in both samples. However, treatment with LY294002 caused a clear reduction in hyperpolarized lactate levels (Fig. 3A). To quantify this drop, we determined Lacmax in each experiment. Lacmax levels dropped in treated cells to 42±7% of control (P=0.005). To further confirm the effect of PI3K inhibition and ascertain that our observations were not dependent on pyruvate concentration, measurements were repeated at higher concentrations of pyruvate (2 mM and 3 mM). Similar results were observed (Fig. 3B) over all concentrations and average Lacmax in treated cells was 42±12% (P<0.0001, n=9) of control.

Figure 3
Effect of PI3K inhibition by LY294002 on hyperpolarized lactate formation in GS-2 perfused cells. A, Evolution of [1-13C]-lactate peak areas after addition of 1 mM hyperpolarized [1-13C]-pyruvate to control or LY294002-treated perfused GS-2 cells, showing ...

To further confirm our findings, we used a two-site chemical exchange model to fit the hyperpolarized 13C MRS data (Fig. 3A continuous line) and determined the apparent pseudo-rate constant of pyruvate-to-lactate conversion (kPyr). Comparison of kPyr also showed a significant reduction with LY294002 treatment over all concentrations. Average kPyr of treated cells was 43±20% (P<0.0001, n=9) of control, similar to the reduction in Lacmax. The reductions in kPyr correlated with the reductions in Lacmax (R2= 0.93), indicating that both methods of analysis yield similar results (Fig. 3C).

Furthermore, T1 values obtained from the fit demonstrated that treatment did not significantly affect the relaxation of hyperpolarized species and therefore did not present a confounding factor in our studies.

Modulation of metabolites by PI3K inhibitor treatment was detected by 31P MRS

31P spectra of control and treated cells were acquired prior to and following hyperpolarized 13C MRS to confirm cell viability during the hyperpolarized study and to detect alterations of endogenous metabolites following PI3K inhibition. Nucleotide triphosphate (NTP) levels increased steadily over the course of all studies, indicating sustained cell viability and confirming that exposure of cells to hyperpolarized pyruvate did not affect cell viability or proliferation (data not shown).

31P MR spectra (Fig. 4) also indicated that treatment with LY294002 resulted in a significant drop in PC to 34±9% of control (P=0.006) and phosphoethanolamine (PE) to 49±7% of control (P=0.006). NTP levels did not change significantly following inhibitor treatment (P=0.6).

Figure 4
Effect of PI3K inhibition on endogenous metabolites detected by 31P MRS. 31P MR spectrum obtained from perfused GS-2 cells. Metabolites detectable in spectrum: PE, phosphoethanolamine; PC, phosphocholine; Pi ex, extracellular inorganic phosphate; Pi in ...

The drop in hyperpolarized lactate is associated with a drop in HIF-1αlevels, LDH expression and LDH activity in GS-2 cells

Since the conversion of pyruvate to lactate in a cellular system could be affected by several independent processes, it was necessary to ascertain that the decrease in hyperpolarized lactate levels was indeed due to a drop in HIF-1α expression downstream of PI3K inhibition, as hypothesized. To this end, we determined LDH activity, LDH expression and HIF-1α expression.

LDH activity was measured in lysates of control and treated cells over a range of pyruvate concentrations, allowing for the determination of the kinetic parameters of the LDH-catalyzed reaction (Fig. 5A). Enzyme Vmax was 20.6±1.0 μmoles NADH/min/107 cells in control cells. Following PI3K inhibition, the activity decreased significantly to 9.8±0.4 μmoles NADH/min/107 cells, or 48±4% of control (P=0.008). The drop in cellular LDH activity was, within experimental error, the same as the drop in Lacmax observed using hyperpolarized 13C MRS. The KM values remained unchanged between control and treated cells (P=0.29). This suggested that the drop in Lacmax was due to a drop in cellular LDH activity, which was caused by a decrease in active enzyme concentration.

Figure 5
Effect of PI3K inhibition by LY294002 on LDH activity, LDH levels and HIF-1αlevels in GS-2 and MDA-MB-231 cells. A, Vmax of LDH activity in cell lysates, showing a decrease in the activity with PI3K inhibition. B, Western blot analysis revealing ...

To confirm the drop in LDH levels, the effect of LY294002 on LDH expression was determined first by Western blotting to assess protein levels, and then by RT-PCR to determine mRNA levels. Western blotting revealed a discernable drop in LDHA protein levels (Fig. 5B), while no difference in LDHB levels was seen (data not shown). The mRNA expression levels of LDHA also dropped significantly to 49±16% of control (P=0.0002) (Fig. 5C). Finally, we investigated levels of HIF-1α in control and treated cells. Consistent with HIF-1 being responsible for regulation of LDH expression, LY294002 treatment led to decreased levels of HIF-1α (Fig. 5B). Taken together, these data are in line with the proposed mechanism that the drop in Lacmax was a result of reduced cellular LDH activity due to lowered HIF-1α levels following PI3K inhibition.

Additionally, it was necessary to study the effects of LY294002 treatment on NADH, the cofactor of LDH necessary for its activity. Previous studies have shown that reduced hyperpolarized pyruvate-to-lactate flux can be caused by depletion of the NAD(H) pool in apoptotic cells (27). However, we found that PI3K inhibition with LY294002 had no significant effect on the concentration of NADH. NADH levels were 0.997±0.137 nmol/107 cells in control cells and 0.882±0.098 nmol/107 cells in treated cells (P=0.31). The ratio of NADH to total NAD(H) was also not significantly changed, at 0.402±0.014 in control compared to 0.335±0.058 in treated cells (P=0.18).

Control studies confirm specificity in GS-2 cells

To assess the specificity of our findings, GS-2 cells were also treated with the clinically relevant inhibitor everolimus, which targets mTOR downstream of PI3K, and with temozolamide, a DNA damaging agent that is not implicated in the PI3K signaling pathway. Treatment with everolimus resulted in inhibition of signaling as evidenced by a drop in phosphorylated 4E-BP1 levels (data not shown) and inhibition in cell proliferation to 45±9% of control (P=0.001). In 13C MRS studies, Lacmax dropped to 76±5% of control (P=0.003, n=4), and LDH activity dropped to 63±4% of control (P=0.003). In contrast, treatment with temozolomide resulted in inhibition in cell proliferation to 70±10% of control (P=0.03), but immunoblotting showed no signal inhibition (data not shown). In line with the unaltered signaling, hyperpolarized 13C MRS studies showed no change in Lacmax levels (P > 0.1, n=4) and LDH activity assays demonstrated no observable differences in Vmax levels (P=0.7).

Findings are confirmed in MDA-MB-231 cells

To assess the generality of our findings, the effect of PI3K inhibition was also investigated in the human breast adenocarcinoma cell line, MDA-MB-231. Similar to GS-2 cells, and as previously reported (22), inhibition of PI3K signaling with LY294002 resulted in decreased cell proliferation and a substantial drop in 4E-BP1 phosphorylation (data not shown).

Hyperpolarized studies were repeated in MDA-MB-231 cells, resulting in similar observations to those made in GS-2 cells. Hyperpolarized lactate levels in treated cells decreased significantly, independent of hyperpolarized pyruvate concentration presented to the cells. On average, Lacmax dropped to 71±15% of control (P=0.001, n=8), while kPyr dropped to a comparable 63±38% (P=0.02, n=6).

As illustrated in Figure 5A LDH Vmax decreased significantly to 69±12% in treated cells from 6.1±0.8 μmoles NADH/min/107 cells to 4.1±0.3 μmoles NADH/min/107 cells (P=0.01, n=4). As in GS-2 cells, the drop in LDH activity was, within experimental error, the same as the drop in Lacmax. KM remained unchanged (P=0.91, n=4). Western blots revealed a drop in LDHA, as well as in HIF-1α in LY294002-treated cells compared to controls (Fig. 5B), while there was no apparent effect on LDHB levels. mRNA levels dropped to 41±20% of control (Fig. 5C).

31P MR spectra (data not shown) indicated that treatment with LY294002 resulted in a decrease in PC to 80±17% relative to control, though this did not reach statistical significance (P=0.17). Similarly, there was a drop to 78% of control in PC following treatment when a cell extract was examined, in line with the decrease of 76±4% (P=0.002, n=4) seen in our previously published study.

In vivo studies show a drop in lactate-to-pyruvate ratio

To assess the utility of hyperpolarized MRS to monitor PI3K inhibition in vivo we performed a small proof-of-principle study and monitored the effect of everolimus on GS-2 tumor xenografts probing treatment effect on the lactate-to-pyruvate ratio as previously described (42). Figure 6 summarizes our findings demonstrating that tumor growth inhibition in treated animals (n=2, dotted lines) was associated with a drop in lactate-to-pyruvate ratio within the tumor. In contrast, tumor growth in control animals (n=2, continuous liens) was associated with an increase in this ratio.

Figure 6
Effect of everolimus treatment on GS-2 tumor xenografts. A, coronal image (7 mm from the surface coil) overlaid with tumor voxels (top) illustrating the origin of 2D-MRSI spectra (middle) and overlay of relative lactate-to-pyruvate ratio maps (bottom) ...

DISCUSSION

Novel therapeutic approaches are increasingly targeting specific molecular genetic events associated with cancer. These advances are leading to more personalized cancer treatment and are expected to result in improved response and reduced toxicity. However, several challenges remain. Most significantly, many targeted therapies result in tumor stasis, rather than shrinkage. Consequently there is a critical need for noninvasive functional imaging biomarkers that confirm drug delivery and molecular drug activity at the tumor site. Here we demonstrate, to our knowledge for the first time, the application of hyperpolarized 13C MRS in the detection of drug target modulation in response to treatment with inhibitors of PI3K signaling.

In this study, PI3K signal inhibition was studied in two cell lines of different cancer types and with different genetic backgrounds. In both cell lines, successful blockade of signaling was associated with a drop in hyperpolarized lactate levels. The drop in hyperpolarized lactate correlated with reduced cellular LDH activity following reduction in HIF-1α levels downstream of PI3K. Further studies are needed to confirm our findings across a wide panel of cell lines. Nonetheless, our initial findings are promising and highlight the potential of hyperpolarized lactate as a biomarker for monitoring the effect of inhibitors of the PI3K pathway.

To assess the potential of this approach for in vivo studies, we also performed a limited proof-of-principle study in xenografts. The drop in lactate-to-pyruvate ratio following treatment was in line with the findings in treated cells and likely indicates a drop in the conversion of hyperpolarized pyruvate into lactate within the inhibited tumors. In contrast, the increase in the pyruvate-to-lactate ratio in control tumors is in line with previous work monitoring tumor progression and could be reflecting increased hypoxia and LDH expression within the growing tumor (29). More extensive studies are needed to assess pyruvate metabolism throughout the animal, quantify the dynamics of pyruvate-to-lactate conversion within each voxel, and confirm the underlying biology of the tumor and its mechanistic link to pyruvate metabolism. Nonetheless, this preliminary in vivo study demonstrates the feasibility and potential value of hyperpolarized 13C studies of pyruvate for noninvasive monitoring of the effect of PI3K inhibitors.

Total lactate levels can also be monitored using 1H MRS (44, 45). However, this approach can be of limited utility, particularly in vivo. Lactate and lipid peaks usually overlap, such that monitoring modulations in lactate can be difficult even when methods for lipid suppression are applied. More importantly, lactate is often associated with poorly vascularized necrotic regions. In this case, the lactate is metabolically inactive and thus would provide little information with regard to the effects of treatment.

The mechanism by which the PI3K pathway interacts with HIF-1 has been thoroughly studied. The PI3K phosphorylation cascade regulates the eIF4F ribosomal complex that is necessary for the translation of HIF-1α (35, 46). In addition, several studies have shown that LY294002 has the ability to reduce HIF-1α levels (47, 48). HIF-1 is responsible for regulating expression of LDHA and other glycolytic enzymes (31, 37). Our results are therefore consistent with these studies, as we show that expression of HIF-1α and LDHA was affected by inhibition of PI3K. This serves to validate our findings by providing the mechanistic underpinnings of hyperpolarized lactate as a biomarker of PI3K signaling.

We have previously shown that PI3K inhibition causes a significant decrease in PC (22). Consistent with these findings, in this study we also observed a drop in PC in both GS-2 and MDA-MB-231 cells. Importantly, the decrease in PC following PI3K inhibition may be explained by the same mechanism that is controlling the modulation of hyperpolarized lactate, namely the drop in HIF-1α levels. The expression of choline kinase, the enzyme responsible for PC synthesis, was recently shown to be regulated by HIF-1 (49). Accordingly, the drop in HIF-1α observed in our treated cells is likely to lead not only to a drop in LDH expression and hyperpolarized lactate formation, but also to a drop in choline kinase expression, and thus a drop in PC. It should however be noted that whereas modulation of PC was observed in this and previous work, it was more modest than the drop in hyperpolarized lactate, required a longer acquisition time, and was more difficult to quantify due to the overlap of PC with other metabolites. This further highlights the value of hyperpolarized lactate as a biomarker of PI3K signal inhibition.

Hyperpolarized 13C MRS has now been extensively applied in animal studies and the use of hyperpolarized pyruvate to monitor tumor metabolism is entering clinical trials at our institution. Of note, studies at lower and more clinically relevant field strengths are facilitated by the slightly longer T1 of the carbonyl carbon (50). With this in mind, the work described here demonstrates that hyperpolarized lactate has a promising application as a noninvasive spectroscopic imaging biomarker of PI3K signaling, with potential to inform on drug delivery and efficacy for a range of emerging targeted therapies in future clinical trials.

Acknowledgments

We thank Rahwa Iman, Mark Albers, David Joun, Lucas Carvajal, and Samara Nebenzahl for valuable discussions and assistance in performing some of the experiments.

This work was supported by NIH grants R21 CA120010-01A1, RO1 CA130819, NIH/NCRR UCSF-CTSI Grant UL1 RR024131-01, UC Discovery grant ITL-BIO04-10148 and UCSF Brain Tumor SPORE CA097257, in conjunction with GE Healthcare

References

1. Fry MJ. Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play? Breast Cancer Res. 2001;3:304–12. [PMC free article] [PubMed]
2. Brader S, Eccles SA. Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori. 2004;90:2–8. [PubMed]
3. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003;4:257–62. [PubMed]
4. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554. [PubMed]
5. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005;4:988–1004. [PubMed]
6. Ward S, Sotsios Y, Dowden J, Bruce I, Finan P. Therapeutic potential of phosphoinositide 3-kinase inhibitors. Chem Biol. 2003;10:207–13. [PubMed]
7. Workman P, Clarke PA, Guillard S, Raynaud FI. Drugging the PI3 kinome. Nat Biotechnol. 2006;24:794–6. [PubMed]
8. Billottet C, Grandage VL, Gale RE, et al. A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene. 2006;25:6648–59. [PubMed]
9. Garlich JR, De P, Dey N, et al. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res. 2008;68:206–15. [PubMed]
10. Endersby R, Baker SJ. PTEN signaling in brain: neuropathology and tumorigenesis. Oncogene. 2008;27:5416–30. [PubMed]
11. Chakravarti A, Palanichamy K. Overcoming therapeutic resistance in malignant gliomas: current practices and future directions. Cancer Treat Res. 2008;139:173–89. [PubMed]
12. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol. 2008;8:393–412. [PubMed]
13. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed. 1992;5:303–24. [PubMed]
14. Kvistad KA, Bakken IJ, Gribbestad IS, et al. Characterization of neoplastic and normal human breast tissues with in vivo (1)H MR spectroscopy. J Magn Reson Imaging. 1999;10:159–64. [PubMed]
15. de Certaines JD, Larsen VA, Podo F, Carpinelli G, Briot O, Henriksen O. In vivo 31P MRS of experimental tumours. NMR Biomed. 1993;6:345–65. [PubMed]
16. Evelhoch JL, Gillies RJ, Karczmar GS, et al. Applications of magnetic resonance in model systems: cancer therapeutics. Neoplasia. 2000;2:152–65. [PMC free article] [PubMed]
17. Leach MO, Verrill M, Glaholm J, et al. Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment. NMR Biomed. 1998;11:314–40. [PubMed]
18. Vigneron D, Bollen A, McDermott M, et al. Three-dimensional magnetic resonance spectroscopic imaging of histologically confirmed brain tumors. Magn Reson Imaging. 2001;19:89–101. [PubMed]
19. Ronen SM, Jackson LE, Beloueche M, Leach MO. Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells. Br J Cancer. 2001;84:691–6. [PMC free article] [PubMed]
20. Chung YL, Troy H, Banerji U, et al. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino, 17-demethoxygeldanamycin (17AAG) in human colon cancer models. J Natl Cancer Inst. 2003;95:1624–33. [PubMed]
21. Beloueche-Babari M, Jackson LE, Al-Saffar NM, Workman P, Leach MO, Ronen SM. Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition. Cancer Res. 2005;65:3356–63. [PubMed]
22. Beloueche-Babari M, Jackson LE, Al-Saffar NM, et al. Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells. Mol Cancer Ther. 2006;5:187–96. [PubMed]
23. Koul D, Shen R, Kondo Y, et al. Cellular and in vivo activity of a novel PI3K inhibitor PX-866 for treatment of human glioblastoma. Neuro-oncology. 2009 In Press.
24. Ardenkjaer-Larsen JH, Fridlund B, Gram A, et al. Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR. Proc Natl Acad Sci U S A. 2003;100:10158–63. [PubMed]
25. Golman K, Zandt RI, Lerche M, Pehrson R, Ardenkjaer-Larsen JH. Metabolic imaging by hyperpolarized 13C magnetic resonance imaging for in vivo tumor diagnosis. Cancer Res. 2006;66:10855–60. [PubMed]
26. Kohler SJ, Yen Y, Wolber J, et al. In vivo 13 carbon metabolic imaging at 3T with hyperpolarized 13C-1-pyruvate. Magn Reson Med. 2007;58:65–9. [PubMed]
27. Day SE, Kettunen MI, Gallagher FA, et al. Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy. Nat Med. 2007;13:1382–7. [PubMed]
28. Chen AP, Albers MJ, Cunningham CH, et al. Hyperpolarized C-13 spectroscopic imaging of the TRAMP mouse at 3T-initial experience. Magn Reson Med. 2007;58:1099–106. [PubMed]
29. Albers MJ, Bok R, Chen AP, et al. Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res. 2008;68:8607–15. [PMC free article] [PubMed]
30. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4:891–9. [PubMed]
31. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell. 2008;13:472–82. [PubMed]
32. Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem. 1994;269:23757–63. [PubMed]
33. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem. 2002;277:27975–81. [PubMed]
34. Arsham AM, Plas DR, Thompson CB, Simon MC. Phosphatidylinositol 3-kinase/Akt signaling is neither required for hypoxic stabilization of HIF-1 alpha nor sufficient for HIF-1-dependent target gene transcription. J Biol Chem. 2002;277:15162–70. [PubMed]
35. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 2001;15:807–26. [PubMed]
36. Firth JD, Ebert BL, Ratcliffe PJ. Hypoxic regulation of lactate dehydrogenase A. Interaction between hypoxia-inducible factor 1 and cAMP response elements. J Biol Chem. 1995;270:21021–7. [PubMed]
37. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 2006;441:437–43. [PubMed]
38. Ronen SM, Rushkin E, Degani H. Lipid metabolism in T47D human breast cancer cells: 31P and 13C-NMR studies of choline and ethanolamine uptake. Biochim Biophys Acta. 1991;1095:5–16. [PubMed]
39. Brindle KM. NMR methods for measuring enzyme kinetics in vivo. Prog Nucl Magn Reson Spectrosc. 1988;20:257–93.
40. Vassault A. Lactate dehydrogenase. Methods of Enzymatic Analysis. 1983:3.
41. Bernofsky C, Swan M. An improved cycling assay for nicotinamide adenine dinucleotide. Anal Biochem. 1973;53:452–8. [PubMed]
42. Park I, Larson P, Zeirhut ML, et al. Hyperpolarized 13C MR Metabolic Imaging: Application to Brain Tumors. Neuro Oncol. 2009 in press. [PMC free article] [PubMed]
43. Naressi A, Couturier C, Castang I, de Beer R, Graveron-Demilly D. Java-based graphical user interface for MRUI, a software package for quantitation of in vivo/medical magnetic resonance spectroscopy signals. Comput Biol Med. 2001;31:269–86. [PubMed]
44. Nelson SJ. Multivoxel magnetic resonance spectroscopy of brain tumors. Mol Cancer Ther. 2003;2:497–507. [PubMed]
45. Bhujwalla ZM, Glickson JD. Detection of tumor response to radiation therapy by in vivo proton MR spectroscopy. Int J Radiat Oncol Biol Phys. 1996;36:635–9. [PubMed]
46. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol. 2001;21:3995–4004. [PMC free article] [PubMed]
47. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ. 2001;12:363–9. [PubMed]
48. Mabjeesh NJ, Willard MT, Frederickson CE, Zhong H, Simons JW. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3′-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res. 2003;9:2416–25. [PubMed]
49. Glunde K, Shah T, Winnard PT, Jr, et al. Hypoxia regulates choline kinase expression through hypoxia-inducible factor-1 alpha signaling in a human prostate cancer model. Cancer Res. 2008;68:172–80. [PubMed]
50. Chen AP, Tropp J, Hurd RE, et al. In vivo hyperpolarized 13C MR spectroscopic imaging with 1H decoupling. J Magn Reson. 2009;197:100–6. [PMC free article] [PubMed]